A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
about
Extended-field irradiation for locally advanced cervical cancerABC3 Consensus Commented from the Perspective of the German GuidelinesProviding Doctors With High-Quality Information: An Updated Evaluation of Web-Based Point-of-Care Information SummariesOptimal management of hormone receptor positive metastatic breast cancer in 2016ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answersDilemma of first line regimens in metastatic pancreatic adenocarcinomaESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO AwardRadionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerImproving access to high-cost cancer drugs in Latin America: Much to be done.Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.ABC3 Consensus: Assessment by a German Group of ExpertsBreast Cancer Is Our Global Responsibility.Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review.Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.Dynamic Assessment of Value During High-Cost Cancer Treatment: A Response to American Society of Clinical Oncology and European Society of Medical Oncology.New Expensive Anticancer Agents: Which Role Is Played by Quality-Adjusted Life-Years in the Selection of a Specific Treatment?Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countriesNew Frameworks to Assess Value of Cancer Care: Strengths and LimitationsEssential medicines for cancer: WHO recommendations and national priorities.Perceptions of Oncologists, Healthcare Policy Makers, Patients and the General Population on the Value of Pharmaceutical Treatments in Oncology.Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology.Health technology assessment and value: the cancer value label (CAVALA) methodology.Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).Low-value practices in oncology contributing to financial toxicity.Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature.Application of the American Society of Clinical Oncology frameworks to compare tyrosine kinase inhibitors used in first line treatment of metastatic renal cell carcinoma: Had we solved the mystery?Early market access of cancer drugs in the EU.Dynamic value assessments in oncology supported by the PACE Continuous Innovation Indicators.Interpretation of lung cancer study outcomes.Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer.Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs.The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel.Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.Is regorafenib providing clinically meaningful benefits to pretreated patients with metastatic colorectal cancer?Do Contemporary Randomized Controlled Trials Meet ESMO Thresholds for Meaningful Clinical Benefit?Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund.A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer.Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned.Anti-angiogenic agents in ovarian cancer: past, present, and future.
P2860
Q26471206-902B690D-EF79-4E11-9AA1-6413E18B571FQ26768665-4F9C21E4-65E3-4374-8F53-1BDB62A940ACQ26770893-2B18E0C1-70D9-4BDA-BA68-7966EA143605Q26777683-A2B79DF0-0B9F-4878-9701-14E33EE927F8Q28066272-1D3B31DD-C878-4C5D-A37E-2BF14D35F2CEQ28077147-D41F7C73-9D6A-42A7-AEB2-DB6C97863116Q28079204-0AB107E3-7700-45CA-8BE4-20DB1C5BAC89Q28079918-935AE8CF-F0B8-4F8D-B0E4-BEA032EC7BDFQ30235988-78B8D6D5-75E5-4BA1-BD1D-3FB0A418CF19Q30313818-2231680D-5C2A-44B4-AC62-E8420FD7E017Q30315301-F3D6405D-08CA-4108-A6C7-6E22A6EA7954Q30315429-3E99ED6B-2BC5-4724-A1D3-FA77C65295BAQ31108599-DE853CEA-1B68-41CE-86DC-2E83B874240BQ33441606-5C9EEC9C-595E-4A1F-AE6D-917AE3DE9F45Q33756769-A46D208C-3FD9-4571-B060-596D4C9BF715Q33859608-DF7FA795-8921-400D-A57F-6CE45689168EQ36305457-88925FAD-F6B2-4388-84A8-966324C58415Q36344226-9A2CF016-0942-4E61-B9C3-D6D2407CB3EBQ37017054-54DC6957-2F80-4020-9EFE-3E8460D6CC49Q37298515-039EC42D-801C-4C47-B59E-3E2DDF89C653Q37373222-EB48922E-CBA6-4963-B165-2DA2A0173F55Q37458781-48DEA564-16DD-4922-B155-1F9F5D6FAA15Q37525138-C1A7DA56-A4C8-4896-A7D1-215C1354A85AQ37692633-CF5E7217-64F5-487C-8F09-CB58D531EA40Q37720714-CAD769DD-41E1-4A43-A731-34511EFECB76Q37742842-EB227EFB-5F41-497E-A818-2530A5FCFA5AQ38598277-5C4C5CEE-EC28-46DF-8446-0BC209D4D198Q38612833-30FA2C3E-0E12-46C9-BA54-7BE701F37AE2Q38651603-CC4F2200-9302-4D69-B09B-350BB13D6A83Q38682736-62CAD9A1-A0EB-4496-9586-7FB20552665AQ38701620-C9726442-EB3C-4C32-928C-057DE9B298F5Q38709350-89BF78AF-F1B1-46BD-8F78-04F5EA293888Q38724502-23DB3CDA-C25D-400E-B43B-BAF9A584CAE5Q38737493-08AAE049-642B-44CB-904D-BD2D048D5B4BQ38796209-2CE354AC-C83B-4C90-A3B6-DDB6563EA21AQ38811530-1F6E8D0F-690C-4315-ABB6-D923AF4E00B7Q38814615-1C6AEF93-A1D4-4EF3-B426-50237A594937Q38839151-2B8C7829-C0FB-4AAF-9E5B-8E32CEDAF987Q38872226-939B80D6-72A1-4349-8C19-831A5945FBC8Q38872239-88B0C2A6-D935-449C-9C87-1449B6B57C7F
P2860
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A standardised, generic, valid ...... cal Benefit Scale (ESMO-MCBS).
@en
type
label
A standardised, generic, valid ...... cal Benefit Scale (ESMO-MCBS).
@en
prefLabel
A standardised, generic, valid ...... cal Benefit Scale (ESMO-MCBS).
@en
P2093
P50
P356
P1433
P1476
A standardised, generic, valid ...... ical Benefit Scale (ESMO-MCBS)
@en
P2093
C Zielinski
M J Piccart
N I Cherny
P304
P356
10.1093/ANNONC/MDV249
P577
2015-05-30T00:00:00Z